Mallinckrodt Pharmaceuticals and Endo have agreed to combine in a nearly $7bn deal after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis.
Endo (NDOI) stock gains as the company is in pact with Mallinckrodt (MNKTQ) to merge in a $6.7B deal, creating a Dublin-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results